Inhibition of Ca2+ signaling and glucagon secretion in mouse pancreatic alpha-cells by extracellular ATP and purinergic receptors.
Glucagon secreted from pancreatic alpha-cells plays a critical role in glycemia, mainly by hepatic glucose mobilization. In diabetic patients, an impaired control of glucagon release can worsen glucose homeostasis. Despite its importance, the mechanisms that regulate its secretion are still poorly understood. Since alpha-cells are particularly sensitive to neural and paracrine factors, in this report we studied the role of purinergic receptors and extracellular ATP, which can be released from nerve terminals and beta-cell secretory granules. Using immunocytochemistry, we identified in alpha-cells the P2 receptor subtype P2Y1, as well as the P1 receptors A1 and A2A. In contrast, only P2Y1 and A1 receptors were localized in beta-cells. To analyze the role of purinergic receptors in alpha-cell function, we studied their participation in Ca2+ signaling. At low glucose concentrations, mouse alpha-cells exhibited the characteristic oscillatory Ca2+ signals that lead to secretion. Application of ATP (1-10 microM) abolished these oscillations or reduced their frequency in alpha-cells within intact islets and isolated in culture. ATPgammaS, a nonhydrolyzable ATP derivative, indicated that the ATP effect was mainly direct rather than through ATP-hydrolytic products. Additionally, adenosine (1-10 microM) was also found to reduce Ca2+ signals. ATP-mediated inhibition of Ca2+ signaling was accompanied by a decrease in glucagon release from intact islets in contrast to the adenosine effect. Using pharmacological agonists, we found that only P2Y1 and A2A were likely involved in the inhibitory effect on Ca2+ signaling. All these findings indicate that extracellular ATP and purinergic stimulation are effective regulators of the alpha-cell function.
Tudurí
Eva
E
Institute of Bioengineering, Miguel Hernandez University, Elche, Spain.
Filiputti
Eliane
E
Carneiro
Everardo M
EM
Quesada
Ivan
I
D000241:Adenosine / Q000494:pharmacology; D000255:Adenosine Triphosphate / Q000031:analogs & derivatives / Q000494:pharmacology*; D000818:Animals; D020013:Calcium Signaling / Q000187:drug effects*; D005110:Extracellular Space / Q000187:drug effects / Q000502:physiology; D005934:Glucagon / Q000378:metabolism*; D050416:Glucagon-Secreting Cells / Q000187:drug effects* / Q000378:metabolism*; D005947:Glucose / Q000494:pharmacology; D007150:Immunohistochemistry; D066298:In Vitro Techniques; D051379:Mice; D018613:Microscopy, Confocal; D019899:Paracrine Communication / Q000187:drug effects / Q000502:physiology; D043682:Receptor, Adenosine A1 / Q000187:drug effects; D043705:Receptor, Adenosine A2A / Q000187:drug effects; D011983:Receptors, Purinergic / Q000187:drug effects / Q000502:physiology*; D018048:Receptors, Purinergic P2 / Q000187:drug effects; D058472:Receptors, Purinergic P2Y1
C546383:P2ry1 protein, mouse; D043682:Receptor, Adenosine A1; D043705:Receptor, Adenosine A2A; D011983:Receptors, Purinergic; D018048:Receptors, Purinergic P2; D058472:Receptors, Purinergic P2Y1; C022571:adenosine 5'-O-(3-thiotriphosphate); D000255:Adenosine Triphosphate; D005934:Glucagon; D005947:Glucose; D000241:Adenosine